Issues

Temozolomide treatment in patients with metastatic colorectal cancer led to inactivation of mismatch repair genes and increased tumor mutational burden that could be monitored in the tissue and blood.

In both preclinical models and two phase I clinical trials of non–small cell lung cancer with EGFR exon 20 mutations, the selective EGFR inhibitor sunvozertinib demonstrated manageable safety and antitumor activity.

A prospective observational study confirms the value of molecular residual disease (MRD) for patients with stage I–IIIA non–small cell lung cancer after resection, highlighting the negative predictive value of longitudinal undetectable MRD.

A synthetic essentiality framework identified tryptophan 2,3-dioxygenase 2 (TDO2) as an essential effector of APC-deficient tumorigenesis, and its inhibition blocks kynurenine–aryl hydrocarbon receptor–induced glycolysis and tumor immune suppression.

Dual treatment with IFNα and anti–PD-1-based immunotherapies may be an effective combination strategy for patients with hepatocellular carcinoma.

Among common dietary supplements, vitamin E intake increases cancer immunotherapy responses by directly inhibiting the SHP1 checkpoint in dendritic cells, which improves antigen presentation and activates T-cell antitumor immunity.

The detection of IRF2BP2 at the intersection of cell-intrinsic inflammatory signaling and acute myeloid leukemia (AML) dependencies suggests cell-intrinsic hyperinflammation as a vulnerability of AML.

SETD2 heterozygous deletion in diffuse large B-cell lymphoma is associated with somatic hypermutation induced by the enzyme AICDA, leading to DNA damage, reduced apoptosis, and increased lymphomagenesis.

Dependency screening in gastrointestinal stromal tumor identified MOZ and Menin–MLL complexes as complementary chromatin regulators and therapeutic vulnerabilities that control oncogenic transcriptional programs.